Reconnecting

The current page stays visible while onset.to reconnects in the background.

Connection error

onset.to could not restore the live connection within 5 seconds. Reload the page to recover.

Log in

Psilocybin

Psilocybin content spanning clinical trials, mushroom science, public policy, and community discussion around one of the core substances in the psychedelic resurgence.

Most recent Latest added

Most recent Latest added

54 entries

August 7, 2026

Psilocybin therapy for PTSD relies heavily on silence, with patients speaking less during dosing than in preparation or integration sessions

psypost.org · Aug 7, 2026 · Eric W. Dolan

Psilocybin Clinical Research Therapy

July 30, 2026

Psilocybin trial for military veterans with PTSD highlights clinical interest in psychedelic-assisted treatment and the challenges of study design and access

psychedelicstoday.com · Jul 30, 2026 · Psychedelics Today

Psilocybin Clinical Research Therapy

Psilocybin-assisted therapy shows promise for veterans with severe treatment-resistant PTSD in a small open-label pilot study with notable symptom reductions

psypost.org · Jul 30, 2026 · Eric W. Dolan

Psilocybin Clinical Research Therapy

July 21, 2026

Q3 2026 psychedelic drug development pipeline bullseye charts map clinical-stage programs, company momentum, and the concentration of targets across indications

psychedelicalpha.com · Jul 21, 2026

LSD Psilocybin Clinical Industry +7

July 20, 2026

"Journeys" follows psilocybin therapy through personal healing stories and clinical context, highlighting preparation, guided sessions, and integration in mental health care

psychedelicstoday.com · Jul 20, 2026 · Psychedelics Today

Psilocybin Clinical Mainstream Therapy

July 19, 2026

New study links psilocybin-assisted therapy to lasting reductions in depression symptoms and changes in brain network flexibility over several months

sciencedaily.com · Jul 19, 2026

Psilocybin Clinical Research Therapy

July 16, 2026

Compass Pathways reports a post-hoc analysis saying COMP360 trial monitoring and support are distinct from psychotherapy in psilocybin treatment research

ir.compasspathways.com · Jul 16, 2026

Psilocybin Clinical Industry Research

July 14, 2026

Psilocybin therapy for depression faces unresolved FDA, reimbursement, training, and delivery risks even after COMPASS reports two positive phase 3 results

clinicaltrialvanguard.com · Jul 14, 2026 · Moe Alsumidaie

Psilocybin Clinical Industry Policy

July 13, 2026

FDA issues final guidance for psychedelic drug development and schedules a September public hearing on the future of psychedelic therapies

psychedelicalpha.com · Jul 13, 2026

Psilocybin MDMA Clinical Policy Therapy

July 8, 2026

Psilocybin therapy for adult females with anorexia nervosa: pilot study in The British Journal of Psychiatry assessing feasibility, safety and early clinical signals

cambridge.org · Jul 8, 2026

Psilocybin Clinical Research Therapy

July 7, 2026

Compass Pathways reports six-month results from its second Phase 3 trial, saying psilocybin treatment produced rapid and durable effects in treatment-resistant depression

ir.compasspathways.com · Jul 7, 2026

Psilocybin Clinical Industry Research

July 2, 2026

Psilocybin improves sleep quality in patients with chronic cluster headaches, with better rest linked to lower attack burden and broader quality-of-life gains

psypost.org · Jul 2, 2026 · Eric W. Dolan

Psilocybin Clinical Research Therapy

July 1, 2026

Veterans and psychedelics event at RAND examines policy, clinical evidence, and implementation challenges for psychedelic-assisted care in military and veteran settings

rand.org · Jul 1, 2026

Psilocybin MDMA Clinical Policy Therapy

June 28, 2026

An international brain imaging analysis finds psychedelics reorganize cortical connectivity, increasing global integration while reducing localized network segregation

psypost.org · Jun 28, 2026 · Karina Petrova

LSD Psilocybin Clinical Consciousness +2

June 23, 2026

Psilocybin addiction recovery research links immune system inflammation shifts, not brain biomarkers alone, to stronger treatment response and reduced substance use risk

thesporereport.com · Jun 23, 2026 · admin

Psilocybin Clinical Research Therapy

June 13, 2026

Psilocybin's anti-inflammatory and neuroplastic effects are being examined for whether they could help protect the aging brain and reduce dementia-related decline

thesporereport.com · Jun 13, 2026 · admin

Psilocybin Clinical Microdosing Research

June 10, 2026

The therapy requirement in the three most advanced psychedelic drug development programs shapes trial design, scalability, and eventual commercial adoption

cascades-analytics.com · Jun 10, 2026

Psilocybin MDMA Business Clinical Therapy

June 9, 2026

Largest real-world psychedelic study launches to track mental health, wellbeing, and outcomes across naturalistic use at unprecedented global scale

thesporereport.com · Jun 9, 2026 · admin

LSD Psilocybin Clinical Mainstream +5

June 8, 2026

Psychedelics are being investigated for neuroplasticity, inflammation, and mood effects that could help protect the aging brain and support healthier cognitive aging

news.berkeley.edu · Jun 8, 2026 · Kara Manke

LSD Psilocybin Clinical Research +3

June 6, 2026

Psilocybin may directly target Alzheimer’s disease mechanisms by reducing neuroinflammation, promoting neuroplasticity, and potentially slowing cognitive decline

thesporereport.com · Jun 6, 2026 · admin

Psilocybin Clinical Research

June 5, 2026

High-dose magic mushrooms are linked to an Alzheimer's patient's regained speech and mobility in a case report that raises questions about psilocybin's neurological effects

dallasexpress.com · Jun 5, 2026 · Dallas Express

Psilocybin Clinical Research

May 27, 2026

One or two psilocybin doses still reduce depression symptoms weeks later, with antidepressant effects linked to the intensity of the psychedelic experience

psychedelics.co.uk · May 27, 2026

Psilocybin Clinical Research Therapy

May 26, 2026

New study at Sheppard Pratt finds psilocybin-assisted therapy may reduce chronic suicidal ideation in adults, highlighting potential clinical relevance for severe mental health care

morningstar.com · May 26, 2026

Psilocybin Clinical Research Therapy

May 18, 2026

Psilocybin is being considered for phantom limb pain after reports linked psychedelic experiences to reduced pain, altered body perception, and emotional relief

themicrodose.substack.com · May 18, 2026 · Shayla Love

Psilocybin Clinical Research Therapy

Compass Pathways stock rises as psilocybin treatment for resistant depression advances, highlighting investor reaction to clinical progress and regulatory momentum

investors.com · May 18, 2026 · ALLISON GATLIN

Psilocybin Business Clinical Research